Figure 1. Telomere uncapping and anti‐cancer effect induced by Ras signaling inhibition.

The inhibition of FDA‐approved inhibitors targeting key molecules downstream of Ras inhibits the phosphorylation of the shelterin TRF1 and TRF2. This inhibition of phosphorylation triggers telomere uncapping, DDR activation, and anti‐cancer effect in vitro and in vivo.